Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide with Brain Re-irradiation for Recurrent High-Grade Glioma
NCT06501911Phase 1Withdrawn
- Sponsor
- University of Nebraska
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bicalutamide in glioblastoma (GBM) and glioma, sponsored by University of Nebraska. Primary endpoints: Incidence of adverse events (AEs) up to 26 months and Incidence of serious adverse events (SAEs) up to 26 months. Planned start Apr 2025; status: withdrawn.
02
Drugs
bicalutamide
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT06501911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501911.